
    
      This is a phase II, open label, randomized study in patients with unresectable Stage III or
      Stage IV malignant melanoma. Patients will be randomly assigned to two different doses of RTA
      402 administered orally once daily for 28 consecutive days, for up to 18 months.
    
  